There is growing evidence that patients have varying priorities at the end of their life. Some want to focus on maximizing their quality of life, whereas others focus on living longer.1 Current clinical practice prioritizes the latter. For example, most cardiac device trials use overall survival as the primary outcome, instead of quality-adjusted life years (QALYs).2-4 What is left unsaid is that these mortality benefits often come at a cost: discomfort, loss of mobility, polypharmacy with its attendant adverse effects, procedural complications, device failure, or loss of functional status.
Liu A, Curfman G. The Trade-offs When Focusing on the Mortality Benefit. JAMA Intern Med. 2018;178(4):455. doi:10.1001/jamainternmed.2018.0067
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: